All In Biotech

Drug Trial Radar · NCT01955252

Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea

Last checked: Nov 19, 2026Latest source record: Aug 28, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

16,000

Actual

Start

Mar 2013

Primary completion

May 2017

Study completion May 2017

Sponsor

Lead sponsor
Lihir Medical CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Barcelona Institute for Global Health; National Department of Health, Papua New Guinea; World Health Organization; University of Washington
First posted
Oct 7, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 2 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial that the investigators are proposing is a pilot study to determine the effect of the new WHO-yaws eradication strategy in Lihir Island (population 18,000), Papua New Guinea. New treatment policies were developed by WHO in 2012 to replace those of the 1950s. The recommended practice is to offer an initial MDA with azithromycin to the entire population, followed by resurveys every 6 months to detect and treat remaining cases.We will use serology surveys, clinical surveys and ulcer aetiology studies to measure the effect of mass azithromycin treatment on the community burden of yaws infection.

Conditions

  • Yaws

Interventions

  • AzithromycinDrug

    Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay). Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance. Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly. For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Prevalence of yaws latent infectionTime frame: 42 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lihir Medical Centre

    Londolovit, New Ireland Province, Papua New Guinea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.